Buy, Sell, Hold: Cell and Gene Therapy - Part 2 BioPharm International
Go here to read the rest:
Buy, Sell, Hold: Cell and Gene Therapy - Part 2 - BioPharm International
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 Business Wire
Originally posted here:
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 - Business Wire
When a Miracle Cure Is Left on the Shelf Bloomberg
5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit BioSpace
Excerpt from:
5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit - BioSpace
MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial Fierce Biotech
See the article here:
MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech
Fiocruz and GEMMABio announce partnership for the development of gene therapies Fiocruz
More here:
Fiocruz and GEMMABio announce partnership for the development of gene therapies - Fiocruz
Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR PharmiWeb.com
View original post here:
Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR - PharmiWeb.com
The rest is here:
JPMA on Japans Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List -...
Buy, Sell, Hold: Cell and Gene Therapy - Part 3 Pharmaceutical Technology Magazine
See the original post here:
Buy, Sell, Hold: Cell and Gene Therapy - Part 3 - Pharmaceutical Technology Magazine
The role of quality assurance in accelerating drug development for emerging therapies pharmaphorum
Here is the original post:
The role of quality assurance in accelerating drug development for emerging therapies - pharmaphorum
Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of PharmiWeb.com
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress The Manila Times
Go here to read the rest:
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - The Manila Times
Clemson professor Trudy Mackay elected to the National Academy of Medicine Clemson News
See the original post:
Clemson professor Trudy Mackay elected to the National Academy of Medicine - Clemson News
Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer News-Medical.Net
See original here:
Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer - News-Medical.Net
Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon Nature.com
Tailored Genetic Medicine: AAV Gene Therapy and mRNA Vaccines Redefine Healthcare's Future Intelligent Living
Here is the original post:
Tailored Genetic Medicine: AAV Gene Therapy and mRNA Vaccines Redefine Healthcare's Future - Intelligent Living
Diet or genetics: Which has a greater impact on lifespan? India Today
See more here:
Diet or genetics: Which has a greater impact on lifespan? - India Today
Dietary restriction or good genes: new study tries to unpick which has a greater impact on lifespan The Conversation
Here is the original post:
Comparison of blood parameters in two genetically different groups of horses for functional longevity in show jumping - Frontiers
May 23, 2024
Mayo Clinic researchers have demonstrated the safety and potential benefit of stem cell regenerative medicine therapy for patients with subacute and chronic spinal cord injury.
The results of the phase 1 Clinical Trial of Autologous Adipose-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury, known as CELLTOP, were published in Nature Communications.
Illustration shows the process of fat harvest via biopsy, adipose-derived mesenchymal stem cells (AD-MSC) preparation and administration of treatment.
All trial participants had experienced traumatic spinal injury classified as grade A or B on the American Spinal Injury Association Impairment Scale (AIS). Stem cell treatment was initiated on average 11 months after injury. Participants were evaluated over a two-year period.
Key findings:
As reported earlier in Mayo Clinic Proceedings, the first participant in the phase 1 trial was a superresponder who, after stem cell therapy, saw significant improvements in the function of his upper and lower extremities.
"Future research may show whether stem cells in combination with other therapies could be part of a new paradigm of treatment to improve outcomes for patients," says Mohamad Bydon, M.D., a neurosurgeon at Mayo Clinic in Rochester, Minnesota, and the first author of both studies. "Not every patient who receives stem cell treatment is going to be a superresponder. One objective in our future studies is to delineate the optimal treatment protocols and understand why patients respond differently."
Dr. Bydon notes that stem cells' mechanism of action isn't fully understood. The researchers are analyzing changes in participants' MRI and cerebrospinal fluid to identify avenues for potential regeneration. Work is also underway on a larger, controlled trial of stem cell regenerative therapy.
"For years, treatment of spinal cord injury has been limited to stabilization surgery and physical therapy," Dr. Bydon says. "Many historical textbooks state that this condition does not improve. We have seen findings in recent years that challenge prior assumptions. This research is a step forward toward the ultimate goal of improving treatments for patients."
Bydon M, et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. Nature Communications. 2024;15:2201.
Bydon M, et al. CELLTOP clinical trial: First report from a phase I trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury. Mayo Clinic Proceedings. 2020;95:406.
Refer a patient to Mayo Clinic.
Follow this link:
Study finds stem cell therapy is safe and may benefit people with ...